Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983 Dec;80(24):7606-10.
doi: 10.1073/pnas.80.24.7606.

Human natural killer cells, activated lymphocyte killer cells, and monocytes possess similar cytotoxic mechanisms

Human natural killer cells, activated lymphocyte killer cells, and monocytes possess similar cytotoxic mechanisms

G F Burns et al. Proc Natl Acad Sci U S A. 1983 Dec.

Abstract

The relationship between the killing mechanisms of human natural killer (NK) cells, mitogen- and mixed-lymphocyte-culture-induced activated lymphocyte killer (ALK) cells, and monocytes was investigated with a monoclonal antibody. The IgG2 antibody 9.1C3 was prepared from mice immunized with purified human large granular lymphocytes and selected from clones that inhibited NK cell killing. The 9.1C3 antibody bound to all mononuclear cells but not to granulocytes or K562 cells, and it selectively blocked killing of K562 targets by both NK and ALK cells without affecting the binding of effector to target cells. The antibody blocked killing when present from time zero and it still inhibited partially even when added 1 hr after initiation of the lytic reaction. Killing of Epstein-Barr virus-transformed B lymphoblasts by classical cytotoxic T lymphocytes was not inhibited. Of interest, 9.1C3 did block the killing of K562 target cells by cultured peripheral blood monocytes. Other monoclonal antibodies that bound to monocytes did not block killing, and a nonspecific effect of the antibody on monocytes was excluded. These data suggest that NK cells, ALK cells, and monocytes can kill tumor cell targets by using similar lytic mechanisms.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Transplant Rev. 1971;7:3-25 - PubMed
    1. J Immunol. 1979 Sep;123(3):1303-11 - PubMed
    1. J Immunol. 1980 May;124(5):2458-63 - PubMed
    1. J Clin Invest. 1980 Oct;66(4):847-51 - PubMed
    1. J Immunol Methods. 1980;36(3-4):285-91 - PubMed

Publication types

Substances

LinkOut - more resources